How to Get Vyleesi (Bremelanotide) in Oklahoma

What Vyleesi Is and Who Qualifies

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 specifically for generalized hypoactive sexual desire disorder in premenopausal women [1]. The drug works on central nervous system pathways involved in sexual response rather than on peripheral blood flow, distinguishing it from phosphodiesterase inhibitors used in male erectile dysfunction.

Qualification criteria are straightforward. A patient must be premenopausal, must report persistent low sexual desire that causes personal distress, and must not have a condition better explained by relationship factors, another medical disorder, substance use, or medication side effects [2]. The diagnosis is clinical. No single lab result confirms or rules out HSDD, though providers routinely check thyroid function, prolactin, and testosterone to exclude organic causes before prescribing.

Oklahoma places no state-specific restrictions on bremelanotide beyond standard controlled-substance scheduling rules (Vyleesi is not a controlled substance). Any provider with an active Oklahoma medical license and prescriptive authority can write the prescription.

Telehealth Prescribing in Oklahoma

Oklahoma law permits telehealth prescribing of non-controlled medications by providers holding an active Oklahoma license or practicing under the state's telehealth reciprocity provisions [3]. Because bremelanotide carries no DEA scheduling, telehealth visits satisfy prescribing requirements without an in-person exam.

A typical telehealth pathway looks like this: a patient completes an intake form disclosing medical history, current medications, blood pressure readings, and symptom duration. The clinician then conducts a synchronous video visit (audio-only does not meet Oklahoma Medical Board standards for an initial prescribing encounter), confirms the HSDD diagnosis using DSM-5 criteria, reviews contraindications, and transmits the prescription electronically.

HealthRX and several other telehealth platforms offer this service to Oklahoma residents with fulfillment through licensed pharmacies that ship directly to the patient's address. Wait times from consultation to delivery typically range from 5 to 10 business days depending on pharmacy processing and insurance verification.

Patients with uncontrolled hypertension (resting systolic ≥160 mmHg or diastolic ≥100 mmHg) or known cardiovascular disease should not receive bremelanotide, as the drug causes transient blood pressure elevation. The FDA label reports mean increases of 6 mmHg systolic and 3 mmHg diastolic peaking at 2 to 3 hours post-dose [2].

Who Can Prescribe: MD, NP, and PA Scope in Oklahoma

Oklahoma grants full prescriptive authority to physicians (MD and DO) without restriction. Nurse practitioners gained full practice authority under the APRN Practice Act effective November 2024, meaning NPs no longer require a collaborative physician agreement to prescribe most non-controlled medications, including bremelanotide [4].

Physician assistants retain a supervisory agreement requirement under Oklahoma's PA Practice Act but may prescribe Vyleesi when the supervising physician's delegation agreement includes the drug or its therapeutic class. In practice, most women's health and primary care PA agreements encompass sexual health medications.

Specialists who commonly prescribe bremelanotide include gynecologists, sexual medicine physicians, endocrinologists, and primary care providers trained in HSDD evaluation. The ISSWSH (International Society for the Study of Women's Sexual Health) consensus guidelines recommend that any clinician comfortable diagnosing HSDD and monitoring for adverse effects may prescribe pharmacotherapy [5].

Clinical Evidence Supporting Bremelanotide

The RECONNECT trials (two identically designed phase 3 studies, combined N=1,267) randomized premenopausal women with HSDD to bremelanotide 1.75 mg subcutaneous or placebo, self-administered as needed over 24 weeks [6]. The primary endpoint was change from baseline in the Female Sexual Function Index desire domain score. Bremelanotide produced a statistically significant improvement of 0.5 points versus placebo (P<0.001), and 34.6% of bremelanotide patients reported "much improved" or "very much improved" on the Patient Global Impression of Change compared to 22.8% on placebo.

Nausea was the most common adverse event, affecting approximately 40% of patients in the first dose but declining to 2% by month 3 of use [6]. The FDA label recommends taking an antiemetic (ondansetron 8 mg orally 30 minutes prior) if nausea persists beyond the first few administrations [2].

The RECONNECT extension study followed 684 women for up to 60 weeks of open-label use. Efficacy was maintained, and no new safety signals emerged. Mean number of doses per month was 2 to 3, consistent with the as-needed label [7].

Dr. Sheryl Kingsberg, lead investigator on the RECONNECT program, stated in the published trial report: "The effect size is modest but clinically meaningful for a population with limited pharmacologic options" [6]. This framing helps set realistic patient expectations during the prescribing conversation.

Pharmacy Access and 503A Compounding in Oklahoma

Patients filling a brand Vyleesi prescription in Oklahoma have two main channels.

Specialty pharmacy. The brand autoinjector (Vyleesi, marketed by Cosette Pharmaceuticals) is stocked by national specialty pharmacies such as Alto, Optum Specialty, and PillPack. These ship to Oklahoma addresses. Brand list price is approximately $950 for a carton of 4 autoinjectors (as of early 2026), though manufacturer copay cards may reduce out-of-pocket cost to $50 to $100 per fill for commercially insured patients.

503A compounding. Oklahoma-licensed 503A compounding pharmacies may prepare bremelanotide injectable vials for individual patient prescriptions. Under federal law (FDCA Section 503A), a 503A pharmacy compounds pursuant to a valid patient-specific prescription, uses USP-grade ingredients, and does not compound copies of commercially available drugs in identical dosage form unless a clinical reason exists (e.g., the patient requires a different concentration or delivery device) [8]. Many telehealth providers pair prescriptions with compounding pharmacies to offer cost savings, with compounded bremelanotide typically running $150 to $300 per month depending on dose quantity.

Oklahoma Board of Pharmacy regulations require that any pharmacy shipping compounded injectables within the state hold a valid Oklahoma pharmacy license. Out-of-state pharmacies shipping into Oklahoma must hold a nonresident pharmacy license.

Insurance, Prior Authorization, and Cost

Oklahoma Medicaid (SoonerCare) does not cover Vyleesi. The drug is excluded from the preferred drug list, and no exception pathway exists for bremelanotide under the current formulary [9].

Commercial insurers vary. UnitedHealthcare, Blue Cross Blue Shield of Oklahoma, and Aetna each maintain bremelanotide on specialty tiers with prior authorization requirements. A typical prior authorization submission must include:

1. Documentation of HSDD diagnosis (DSM-5 criteria met, duration ≥6 months)
2. Confirmation that distress is patient-reported, not partner-reported
3. Evidence that reversible causes (thyroid dysfunction, hyperprolactinemia, medication side effects) have been evaluated and addressed
4. Statement that the patient is premenopausal
5. Blood pressure readings within the prior 90 days showing resting values below 160/100 mmHg

Turnaround time for prior authorization decisions in Oklahoma is governed by state prompt-pay laws: insurers must respond within 2 business days for non-urgent requests, 24 hours for urgent requests [10].

If a prior authorization is denied, the prescribing clinician may file a peer-to-peer appeal. Common denial reasons include missing labs, failure to document distress, or a claim that the patient has not tried non-pharmacologic therapy first (note: no guideline mandates therapy before medication for HSDD).

Labs and Clinical Workup Before Prescribing

No lab is mandatory before a Vyleesi prescription. The FDA label does not require baseline bloodwork. Standard clinical practice, however, includes screening labs to rule out organic etiologies and satisfy prior authorization requirements.

Most Oklahoma-based prescribers order:

• TSH (thyroid dysfunction causes low libido in up to 5% of premenopausal women) [11]
• Prolactin (hyperprolactinemia suppresses gonadotropins and desire)
• Total and free testosterone (low testosterone is associated with reduced desire, though the threshold is debated)
• Comprehensive metabolic panel (assess renal/hepatic function for drug clearance)
• Blood pressure measurement (taken at the visit or self-reported home readings)

These labs can be drawn at any Quest Diagnostics, LabCorp, or hospital lab in Oklahoma. Telehealth providers typically issue a lab requisition that the patient takes to the nearest draw site. Results are reviewed before prescribing, adding 3 to 5 days to the overall timeline.

Timeline: From Consultation to First Dose

Here is a realistic timeline for an Oklahoma patient starting from scratch:

Days 1 to 2. Complete online intake, schedule video consultation, and receive lab requisition.

Days 3 to 5. Lab draw at local site; results returned to provider.

Days 5 to 7. Video visit, diagnosis confirmed, prescription transmitted.

Days 7 to 12. Pharmacy fills prescription; if prior authorization is required, add 2 to 4 business days. Compounding pharmacies may require 3 to 5 business days for preparation.

Days 10 to 14. Medication arrives via cold-chain shipping (bremelanotide is stored at room temperature per the FDA label, but compounded formulations may require refrigeration depending on the pharmacy's beyond-use dating).

Total elapsed time: 10 to 14 days for straightforward cases, up to 21 days if prior authorization is involved and initially denied.

Transferring an Existing Prescription to Oklahoma

Patients relocating to Oklahoma with an active bremelanotide prescription can transfer it to an Oklahoma-licensed pharmacy. The process follows standard prescription transfer rules under Oklahoma Administrative Code Title 535, Chapter 15. The receiving pharmacist contacts the transferring pharmacy, verifies the prescription, and logs the transfer.

If the prescribing clinician is not licensed in Oklahoma, the patient will need a new prescription from an Oklahoma-licensed provider before the next refill. Telehealth platforms resolve this quickly since the diagnosis is already established and prior records can be forwarded. Expect a 15 to 20 minute re-evaluation visit.

Compounding prescriptions cannot be transferred between pharmacies because they are patient-specific formulations prepared per individual prescription. The patient's new Oklahoma provider must issue a new prescription to the receiving compounding pharmacy.

Safety Monitoring and Ongoing Use

The FDA recommends that patients check blood pressure before each dose during the first month of use and report sustained elevations [2]. After the initial period, periodic blood pressure checks (every 3 to 6 months) are sufficient if readings remain stable.

Focal hyperpigmentation may occur, particularly in darker-skinned patients, due to bremelanotide's melanocortin activity. In the RECONNECT trials, 1% of patients developed localized darkening at the injection site or on the face [6]. This effect is reversible upon discontinuation in most cases.

Follow-up visits (telehealth or in-person) are typically scheduled at 3 months after initiation to assess efficacy, tolerability, and continued indication. Oklahoma does not require refill-by-refill provider encounters for non-controlled medications, so prescriptions can be written for up to 12 months with refills.

Contraindications Specific to Oklahoma Practice

No Oklahoma-specific contraindications exist beyond the FDA label. The absolute contraindications are uncontrolled hypertension and known cardiovascular disease. Relative cautions include hepatic impairment (the drug is hepatically metabolized, though no dose adjustment is specified for mild-to-moderate impairment) and concurrent use of naltrexone (which may reduce bremelanotide efficacy through opioid receptor interactions) [2].

Patients using hormonal contraceptives may continue them. No pharmacokinetic interaction exists between bremelanotide and combined oral contraceptives, IUDs, or implants per FDA review data [2]. Women on flibanserin (Addyi) should not use bremelanotide concurrently, as combined use has not been studied and both agents act on central pathways involved in sexual response.